Finasteride 5 mg is a well-established therapy for benign prostatic hyperplasia (BPH). Lower doses, such as finasteride 1 mg-commonly prescribed for androgenic alopecia-also produce measurable suppression of dihydrotestosterone (DHT) and prostate-specific antigen (PSA). This review examines the available evidence related to finasteride 1 mg with respect to prostate biology, safety, and its theoretical potential in modifying BPH risk when initiated earlier in life and its hypothesis-generating potential for preventive use.
A structured review of PubMed, EMBASE, and the Cochrane Library from January 1990 through January 2026 was performed to identify studies evaluating finasteride 1 mg with prostate-relevant biologic or surrogate outcomes, including PSA suppression and androgen modulation. Pharmacodynamic dose-response studies were reviewed, and landmark randomized controlled trials (RCTs) of finasteride 5 mg in men with BPH were included for clinical context regarding established prostate volume, symptoms, and progression outcomes.
Observational and secondary analyses evaluating long-term exposure to finasteride 1 mg demonstrate consistent biologic effects on prostate-related pathways, most notably suppression of serum PSA. Prostate volume, lower urinary tract symptoms (LUTS), and progression-related outcomes were not predefined primary endpoints in available studies evaluating finasteride 1 mg, and direct evidence demonstrating clinical benefit for these outcomes at the 1 mg dose is lacking.
Finasteride 1 mg produces measurable biologic effects on prostate-related pathways, including suppression of DHT and PSA. However, clinical prostate outcomes-such as reductions in prostate volume, improvement in LUTS, and prevention of disease progression-are supported only by randomized trials evaluating finasteride 5 mg. Finasteride 1 mg may therefore be best considered a hypothesis-generating option for early or preventive strategies in selected younger men. Large RCTs are warranted to determine whether these biologic effects translate into clinically meaningful benefits.
Translational andrology and urology. 2026 Feb 26 [Epub]
Mustafa Farooqi, Paige Bird, Samuel Lassiter, Florian A Stroie
Division of Urology, Cook County Health, Chicago, IL, USA., Midwestern University Chicago College of Osteopathic Medicine, Downers Grove, IL, USA.